CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Idera scientists presented data from preclinical studies on modulation of Toll-Like Receptors (TLRs) 3, 7, and 9 through antisense in three presentations at the Federation of Clinical Immunology Societies (FOCIS) 2009 Annual Meeting held in San Francisco, CA, June 11-14.
